Features of Cell-Mediated Immunity in Children with Congenital Ichthyosis and Their Role in the Pathogenetic Management

Background. Congenital ichthyoses (CIs) are a heterogeneous clinical-etiological group of genodermatoses. Typical clinical symptoms of this disease, regardless of the form, are generalized erythroderma, peeling, itching, hyperkeratosis, severe structural and functional disorders of the epidermal barrier, other organs and systems. Patients have an extremely low quality of life due to changes in appearance, discomfort, constant disease symptoms. Thus far, there are no effective treatment methods for ichthyosis. That is why scientific search for new therapies is the topical issue in pediatrics and pediatric dermatology.

Objective. The aim of the study is to examine the cell-mediated immunity state in patients with CI via assessment of the pattern of lymphocyte subpopulations in peripheral blood. The research was conducted to study the content of the main and small lymphocyte subpopulations in 86 patients with established diagnosis of CI aged from 1 month to 18 years. The diagnosis was made according to the clinical data and the results of molecular genetic testing. Comparative analysis of blood immunological indicators in children with CI and in patients with other immunemediated chronic dermatoses: atopic dermatitis (AD; n = 68) and psoriasis vulgaris (n = 55).

Methods. The level of T lymphocytes, T helpers (Th), cytotoxic T lymphocytes (Tc), B lymphocytes, NK cells, Treg-cells (Treg), activated T helpers (Thact), Th17 lymphocytes in peripheral blood was evaluated via flow cytometry using monoclonal antibodies. Statistical analysis was performed via Statistica 10.0. Differences between the groups were assessed via Mann-Whitney non-parametric test, differences were considered significant at p < 0.05.

Results. A significant increase of activated T-helpers level in peripheral blood was revealed in patients with CI and psoriasis compared to children with AD (p < 0.001), as well as an increased levels of B-lymphocytes and Treg in children with CI (p < 0.05).

Conclusion. Children with CI have shown some features of cell-mediated immunity such as: pathological activation of Th lymphocytes, impaired terminal differentiation of naive CD4+ cells to Thact, Treg, Th17 lymphocytes and their proliferation. Comparative analysis of mentioned immunological indicators in children with CI, psoriasis and AD has shown comparable results of increased Thact lymphocytes levels in patients in CI and psoriasis groups. This results open up potential of using immunobiological drugs of psoriasis target therapy within the new management strategy for children with CI.

1. Oji V, Tadini G, Akiyama M, et al. Revised nomenclature and classification of inherited ichthyoses: results of the First Ichthyosis Consensus Conference in Sorèze 2009. J Am Acad Dermatol. 2010;63(4):607–641. doi: https://doi.org/10.1016/j.jaad.2009.11.020

2. Richard G. Autosomal Recessive Congenital Ichthyosis. 2001 Jan 10 [Updated 2023 Apr 20]. In: GeneReviews® [Internet]. Adam MP, Mirzaa GM, Pagon RA, et al., eds. Seattle (WA): University of Washington, Seattle; 1993–2023. Available online: https://www.ncbi.nlm.nih.gov/books/NBK1420. Accessed on October 19, 2023.

3. Murashkin NN, Avetisyan KO, Ivanov RA, Makarova SG. Congenital Ichthyosis: Clinical and Genetic Characteristics of the Disease. Voprosy sovremennoi pediatrii — Current Pediatrics. 2022;21(5):362–377. (In Russ). doi: https://doi.org/10.15690/vsp.v21i5.2459

4. Sun Q, Burgren NM, Cheraghlou S, et al. The Genomic and Phenotypic Landscape of Ichthyosis: An Analysis of 1000 Kindreds. JAMA Dermatol. 2022;158(1):16–25. doi: https://doi.org/10.1001/jamadermatol.2021.4242

5. Ikhtioz u detei: Clinical recommendations. Union of Pediatricians of Russia; 2016. p. 6. (In Russ).

6. Lee AY. Molecular Mechanism of Epidermal Barrier Dysfunction as Primary Abnormalities. Int J Mol Sci. 2020;21(4):1194. doi: https://doi.org/10.3390/ijms21041194

7. Malik K, He H, Huynh TN, et al. Ichthyosis molecular fingerprinting shows profound TH17 skewing and a unique barrier genomic signature. J Allergy Clin Immunol. 2019;143(2):604–618. doi: https://doi.org/10.1016/j.jaci.2018.03.021

8. Kondratenko IV, Bologov AA. Pervichnye immunodefitsity: textbook. Moscow: IndeksMed Media; 2020. p. 31. (In Russ).

9. Czarnowicki T, He H, Leonard A, et al. The Major Orphan Forms of Ichthyosis Are Characterized by Systemic T-Cell Activation and Th-17/Tc-17/Th-22/Tc-22 Polarization in Blood. J Invest Dermatol. 2018;138(10):2157–2167. doi: https://doi.org/10.1016/j.jid.2018.03.1523

10. Paller AS, Renert-Yuval Y, Suprun M, et al. An IL-17-dominant immune profile is shared across the major orphan forms of ichthyosis. J Allergy Clin Immunol. 2017;139(1):152–165. doi: https://doi.org/10.1016/j.jaci.2016.07.019

11. Mazereeuw-Hautier J, Vahlquist A, Traupe H, et al. Management of congenital ichthyoses: European guidelines of care, part one. Br J Dermatol. 2019;180(2):272–281. doi: https://doi.org/10.1111/bjd.17203

12. Mazereeuw-Hautier J, Hernández-Martín A, O’Toole EA, et al. Management of congenital ichthyoses: European guidelines of care, part two. Br J Dermatol. 2019;180(3):484–495. doi: https://doi.org/10.1111/bjd.16882

13. Youssefian L, Vahidnezhad H, Saeidian AH, et al. Autosomal recessive congenital ichthyosis: Genomic landscape and phenotypic spectrum in a cohort of 125 consanguineous families. Hum Mutat. 2019;40(3):288–298. doi: https://doi.org/10.1002/humu.23695

14. Sabat R, Wolk K, Loyal L, et al. T cell pathology in skin inflammation. Semin Immunopathol. 2019;41(3):359–377. doi: https://doi.org/10.1007/s00281-019-00742-7

15. Kuptsova DG, Radigina TV, Kurbatova OV, et al. Content of CD4+Т cell subpopulations in predicting the efficacy of biological therapy for psoriasis in children. Medical Immunology (Russia) = Meditsinskaya Immunologiya. 2023;25(5):1071–1078. (In Russ). doi: https://doi.org/10.15789/1563-0625-COC-2704

16. Mansouri Y, Guttman-Yassky E. Immune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted Therapeutics. J Clin Med. 2015;4(5):858–873. doi: https://doi.org/10.3390/jcm4050858

17. Murashkin NN, Opryatin LA, Epishev RV, et al. New Era in Atopic Dermatitis Treatment: Results of Long-Term Dupilumab Administration. Voprosy sovremennoi pediatrii — Current Pediatrics. 2021;20(5):390–395. (In Russ). doi: https://doi.org/10.15690/vsp.v20i5.2312

18. Kuptsova DG, Petrichuk SV, Murashkin NN, et al. Early predictors of efficacy of biological therapy for psoriasis in children. Allergology and Immunology in Pediatrics. 2023;(1):49–52. doi: https://doi.org/10.53529/2500-1175-2023-1-49-52

19. Tausend W, Downing C, Tyring S. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab. J Cutan Med Surg. 2014;18(3):156–169. doi: https://doi.org/10.2310/7750.2013.13125

20. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072. doi: https://doi.org/10.1016/j.jaad.2018.11.057

21. Wollenberg A, Thomsen SF, Lacour JP, et al. Targeting immunoglobulin E in atopic dermatitis: A review of the existing evidence. World Allergy Organ J. 2021;14(3):100519. doi: https://doi.org/10.1016/j.waojou.2021.100519

22. Agache I, Akdis CA, Akdis M, et al. EAACI Biologicals Guidelinesdupilumab for children and adults with moderate-to-severe atopic dermatitis. Allergy. 2021;76(4):988–1009. doi: https://doi.org/10.1111/all.14690

23. Bieber T. Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75(1):54–62. doi: https://doi.org/10.1111/all.13954

24. Ghoreschi K, Balato A, Enerbäck C, Sabat R. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet. 2021;397(10275):754–766. doi: https://doi.org/10.1016/s0140-6736(21)00184-7

25. Briot A, Deraison C, Lacroix M, et al. Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. J Exp Med. 2009;206(5):1135–1147. doi: https://doi.org/10.1084/jem.20082242

26. Reche PA, Soumelis V, Gorman DM, et al. Human thymic stromal lymphopoietin preferentially stimulates myeloid cells. J Immunol. 2001;167(1):336–343. doi: https://doi.org/10.4049/jimmunol.167.1.336

27. Fontao L, Laffitte E, Briot A, et al. Infliximab infusions for Netherton syndrome: sustained clinical improvement correlates with a reduction of thymic stromal lymphopoietin levels in the skin. J Invest Dermatol. 2011;131(9):1947–1950. doi: https://doi.org/10.1038/jid.2011.124

28. Kondratenko IV, Bologov AA. Pervichnye immunodefitsity: textbook. Moscow: IndeksMed Media; 2020. pp. 117–120. (In Russ).

29. Eränkö E, Ilander M, Tuomiranta M, et al. Immune cell phenotype and functional defects in Netherton syndrome. Orphanet J Rare Dis. 2018;13(1):213. doi: https://doi.org/10.1186/s13023-018-0956-6

30. Hannula-Jouppi K, Laasanen SL, Ilander M, et al. Intrafamily and Interfamilial Phenotype Variation and Immature Immunity in Patients With Netherton Syndrome and Finnish SPINK5 Founder Mutation. JAMA Dermatol. 2016;152(4):435–442. doi: https://doi.org/10.1001/jamadermatol.2015.5827

31. Paller AS. Profiling Immune Expression to Consider Repurposing Therapeutics for the Ichthyoses. J Invest Dermatol. 2019;139(3): 535–540. doi: https://doi.org/10.1016/j.jid.2018.08.027

32. Paller AS, Czarnowicki T, Renert-Yuval Y, et al. The spectrum of manifestations in desmoplakin gene (DSP) spectrin repeat 6 domain mutations: Immunophenotyping and response to ustekinumab. J Am Acad Dermatol. 2018;78(3):498–505.e2. doi: https://doi.org/10.1016/j.jaad.2017.10.026

33. Luchsinger I, Knöpfel N, Theiler M, et al. Secukinumab Therapy for Netherton Syndrome. JAMA Dermatol. 2020;156(8):907–911. doi: https://doi.org/10.1001/jamadermatol.2020.1019

34. Yogarajah J, Gouveia C, Iype J, et al. Efficacy and safety of secukinumab for the treatment of severe ABCA12 deficiencyrelated ichthyosis in a child. Skin Health Dis. 2021;1(2):e25. doi: https://doi.org/10.1002/ski2.25